Health Condition 1: I10- Essential (primary) hypertension
Conditions
Interventions
Intervention1: Olmesartan: Tab.olmesartan 20mg an angiotensin receptor blocker given once daily for 3months.
Control Intervention1: Telmisartan: Tab.Telmisartan 40 mg an angiotensin receptor blocker g
Sponsors
ESIC Medical College and Hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1.Adult patients aged 18 years or older 2.Patients who are newly diagnosed with hypertension. 3.Patients of either gender.
Exclusion criteria
Exclusion criteria: 1.Patients receiving any other antihypertensive medication, corticosteroids and immunosuppressive agents 2.Patient with history of renal disease. 3.Pregnant and lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.To compare the cost-effectiveness of olmesartan & telmisartan on reducing blood pressure. 2.To compare the effect of olmesartan & telmisartan on blood pressure in newly diagnosed hypertensive patients. 3.To compare the tolerability of olmesartan and telmisartanTimepoint: 1.Blood pressure will be assessed at baseline,2nd week,4th week,8th week,12th week. 2.tolerability is checked by adverse effects profile at baseline and at 12th week 3.cost-effectiveness assessed by ICER ratio at 12th week. | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate & compare the effect of olmesartan & telmisartan on fasting lipid profile, fasting blood sugar & renal function(serum creatinine). Timepoint: The percentage reduction of fasting blood sugar, fasting lipid profile & renal function(serum creatinine) by 10% of the base line value. | — |
Countries
India
Contacts
Public ContactDrTS Usha sree
ESIC Medical College and Hospital,Sanathnagar,Hyderabad.
Outcome results
None listed